FDA OKs first-of-its-kind T-cell cancer therapy developed by Penn & CHOP

The Food and Drug Administration approved a personalized cellular therapy treatment for leukemia developed by researchers at the University of Pennsylvania and Children ’s Hospital of Philadelphia. The T-Cell therapy, which will be marketed by Novartis as Kymriah, was OK'd as treatment for patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory, or in second or later relapse. In 2012, Penn and Novartis — a Swiss dr ug company that has its U.S headquarters…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news